Skip to main content

Advertisement

Log in

Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Pankey GA (2005) Tigecycline. J Antimicrob Chemother 56:470–480

    Article  CAS  PubMed  Google Scholar 

  2. Wyeth. http://www.wyeth.com/content/getfile.asp?id=491, accessed 01 May 2009

  3. Egi M, Morimatsu H, Wiedermann C, Tani M, Kanazawa T, Suzuki S, Matsusaki T, Shimizu K, Toda Y, Iwasaki T, Morita K (2009) Non-overt disseminated intravascular coagulation scoring for critically ill patients: the impact of antithrombin levels. Thromb Haemost 101:696–705

    CAS  PubMed  Google Scholar 

  4. FDA. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-821_Tygacil_Medr.pdf

  5. Zimmerman JJ, Raible DG, Harper DM, Matschke K, Speth JL (2008) Evaluation of a potential tigecycline–warfarin drug interaction. Pharmacotherapy 28:895–905

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Herwig Pieringer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pieringer, H., Schmekal, B., Biesenbach, G. et al. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol 89, 1063–1064 (2010). https://doi.org/10.1007/s00277-010-0911-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-0911-7

Keywords

Navigation